Presented at the virtual American Society of Clinical Oncology (ASCO) annual meeting, the findings from the S1404 clinical trial demonstrated that, although the PD-1 inhibitor pembrolizumab (Keytruda) came up short in both the intent-to-treat (ITT) population and PD-L1-positive subgroup, relapse-free survival (RFS) was significantly improved compared with those who received either ipilimumab (Yervoy) or high-dose […]
The results of the trial, known as the RELATIVITY-047 study, were presented at the virtual ASCO Annual Meeting that took place June 4-8, 2021. The Dana-Farber Cancer Institute Investigators who co-led the study were thrilled to present that, despite PD-1 blocker nivolumab revolutionizing the treatment of patients with advanced melanoma, this fixed-dose combination of nivolumab […]
Although the MYSTIC phase 3 clinical trial examining durvalumab therapy for non–small-cell lung cancer (NSCLC) did not meet its primary end points – overall survival (OS) and progression-free survival (PFS) – it did show a numerically reduced risk for death with durvalumab (Imfinzi) versus chemotherapy in patients with PD-L1 expression on ≥25% of tumor cells.
The term abscopal effect (from Latin, ab, meaning “away from,” and scopus, meaning “target”) was coined in 1953, specifically referring to effects of ionizing radiation outside the radiated tumor volume. Does the evidence show that, contrary to widely held perception in the field, the abscopal effect is exceedingly rare and is not clinically relevant when […]
In this Original Investigation, JAMA Oncology explores the CheckMate 143 Phase 3 trial, asking whether PD-1 immune checkpoint inhibition with nivolumab improves overall survival compared with bevacizumab treatment for patients with recurrent glioblastoma.